Christine Dirienzo

发表

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

A. Hagenbeek, M. Czuczman, J. Radford, 2012, Blood.

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

M. Deininger, R. Mesa, M. Talpaz, 2019, Leukemia research.

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

H. Dombret, J. Cortes, A. Merchant, 2019, Future oncology.

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).

S. Yeh, J. Byun, S. Grosicki, 2023, Journal of Clinical Oncology.

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

R. Advani, J. Leonard, C. Hofmeister, 2010 .

T cell receptor V-alpha spectratype analysis of a CD4-mediated T cell response against minor histocompatibility antigens involved in severe graft-versus-host disease

Stephen C. Jones, R. Korngold, T. Friedman, 2008 .

T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host Disease

Stephen C. Jones, R. Korngold, G. Murphy, 2006 .

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.